A man receives a third dose of the COVID19 vaccine at Sheba Medical Center on July 14, 2021 in Ramat Gan, Israel.
Amir Levy | beautiful pictures
Israeli researchers said on Saturday that they had found that a three-way course of Pfizer–BioNTech The Covid-19 vaccine offers significant protection against the new omicron variant.
The findings were similar to what is presented by BioNTech and Pfizer at the start of the week, it was an early signal that booster shots could be key to protecting against infection from the newly identified variant.
The study, conducted by the Sheba Medical Center and the Department of Health’s Central Virology Laboratory, compared the blood of 20 people who had received two doses of the vaccine 5-6 months earlier with the same number of people who had received the same vaccine. booster injection a month before.
“People who received a second dose 5 or 6 months ago didn’t have any neutralizing ability against omicrons. While they did have some against delta (strain),” said Gili Regev-Yochay, unit director. Infectious disease in Sheba, said the reporter.
“The good news is that with the booster dose it increases by a hundredfold. There is a significant protection of the booster dose. It is less than neutralizing for the plains, about four times lower,” she said.
The Israeli team says they worked with the actual virus, while the companies used something called a pseudovirus, which is biologically engineered to have omicron-specific mutations.
The following Israeli study a study from South Africa discovered that the omicron variant may partially avoid the protection from two doses.
